Its Advantage Roche As Indian Patent Office Rejects Valcyte Opposition By Indian Groups
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Swiss drug maker Roche has gained a significant lead against two non-government organizations in its fight over patents of anti-infection drug Valcyte (valgancyclovir) after India's Controller of Patents rejected their pleas for pre-grant opposition
You may also be interested in...
Round One Goes To Indian Cos As Roche Loses Patent Fight On Valcyte
MUMBAI - In a judgment that seasoned intellectual property experts predict will impact the course of Indian jurisprudence, the Indian Patent Office has rejected the patent claims of Swiss drug maker Roche over the antiviral drug Valcyte (valgancyclovir) mainly on grounds of lack of inventiveness
Round One Goes To Indian Cos As Roche Loses Patent Fight On Valcyte
MUMBAI - In a judgment that seasoned intellectual property experts predict will impact the course of Indian jurisprudence, the Indian Patent Office has rejected the patent claims of Swiss drug maker Roche over the antiviral drug Valcyte (valgancyclovir) mainly on grounds of lack of inventiveness
Indian Pharma Lobby Calls For Re-examination Of 81 MNC Drug Patents
MUMBAI - As Indian companies battle multinational drug giants for patent rights, the Indian Pharmaceutical Alliance - an association that represents top Indian drug companies - wrote to the Union Ministry of Commerce and Industry Feb. 14 that a large number of pharmaceutical patents granted over the last four years are granted to new forms of known substances and combinations of old drugs